ClinVar Miner

Submissions for variant NM_000132.3(F8):c.6320G>A (p.Gly2107Asp) (rs1190705187)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000756116 SCV000883835 likely pathogenic not provided 2018-06-11 criteria provided, single submitter clinical testing The F8 c.6320G>A; p.Gly2107Asp variant, also known as Gly2088Asp, has been described in at least one individual affected with severe hemophilia A (Santacroce 2008). It is absent from general population databases (1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database), indicating it is not a common polymorphism. The glycine at codon 2107 is highly conserved, and computational algorithms (PolyPhen-2, SIFT) predict that this variant is deleterious. Additionally, another missense variant at this codon (p.Gly2107Ser) and deletion of this amino acid (p.Gly2107del) have been reported in individuals affected with severe hemophilia and are considered pathogenic (see link to FVIII database and references therein). Based on available information, this variant is considered likely pathogenic. References: Factor VIII database: Santacroce R et al. Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A. J Hum Genet. 2008;53(3):275-84.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.